According to the release, 423 members responded to the survey. Anti-VEGF medications, which were ranked as most important, inhibit VEGF, which can cause abnormal blood vessel growth in the eye’s retina and lead to irreversible vision loss, according to the release. This class of drugs was approved by the U.S. Food and Drug Administration in Dec. 2004, allowing ophthalmologists to gain control over wet AMG and hopefully prevent vision loss in patients.
Number two on the list was optical coherence tomography with 23.9 percent of members citing the treatment, followed distantly at 6.6 percent by a glaucoma treatment, Prostamide eye drops.
Several other advances — including premium intraocular lenses, the Femtosecond laser, gene therapy for Leber’s congenital amaurosis and Descemet’s stripping automated endothelial keratoplasty — were each cited by about 3 percent of respondents, according to the release.
Read the AAO’s release about the most important ophthalmology advancements in the past decade. http://aao.org/newsroom/release/20100114.cfm
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
